



NDA 200153/S-003

SUPPLEMENT APPROVAL

Merck Sharp & Dohme Corp.
US Agent for MSD International GmbH
Attention: Catherine Kohler, Pharm. D.
Director Worldwide Regulatory Affairs
P.O. Box 1000
North Wales, PA 19454

Dear Dr. Kohler:

Please refer to your Supplemental New Drug Application (sNDA) dated and received November 26, 2013, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Liptruzet (ezetimibe/atorvastatin) tablets, 10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg, and 10 mg/80 mg.

We acknowledge receipt of your amendments dated November 27, 2013, January 22 and 23, and May 16, 2014. We also acknowledge receipt of your email dated May 2, 2014, that includes the agreed-upon package insert/patient information.

This "Prior Approval" supplemental new drug application provides for a modified formulation utilizing the (b)(4) of atorvastatin calcium trihydrate and the (b)(4) of ezetimibe as drug substances. The supplement also includes associated labeling revisions to the content of labeling (PI/PPI) and carton/container labeling.

APPROVAL & LABELING

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

Sufficient stability has been submitted to support a 24 month expiration date.

WAIVER OF HIGHLIGHTS SECTION

Please note that we have previously granted a waiver of the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of prescribing information.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert, text for the patient package insert [Patient Information]), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

CARTON AND IMMEDIATE CONTAINER LABELS

Submit final printed carton and immediate container labels that are identical to the enclosed carton and immediate container labels as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (June 2008)*. Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission “**Final Printed Carton and Container Labels for approved NDA 200153/S-003.**” Approval of this submission by FDA is not required before the labeling is used.

Marketing the product(s) with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory

comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:

Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion (OPDP)
5901-B Ammendale Road
Beltsville, MD 20705-1266

You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>. Information and Instructions for completing the form can be found at <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see <http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm>.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Kati Johnson, Senior Regulatory Project Manager, at (301) 796-1234.

Sincerely,

{See appended electronic signature page}

Eric Colman, MD
Deputy Director
Division of Metabolism and Endocrinology Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

ENCLOSURES:

- Content of Labeling
- Carton and Container Labeling
 - 10 mg/10 mg strength
 - foil sample (4 tablets)
 - sample carton (7 foil samples, 28 tablets total)
 - trade card (inner)-contains 30 tablets
 - trade card (outer)
 - trade wallet (contains 1 card)
 - trade carton (contains 1 wallet [30 tablets])

- trade carton (contains 3 wallets [90 tablets])
- 10 mg/20 mg strength
 - foil sample (4 tablets)
 - sample carton (7 foil samples, 28 tablets total)
 - trade card (inner)-30 tablets
 - trade card (outer)
 - trade wallet (contains 1 card)
 - trade carton (contains 1 wallet [30 tablets])
 - trade carton (contains 3 wallets [90 tablets])
- 10 mg/40 mg strength
 - foil sample (4 tablets)
 - sample carton (7 foil samples, 28 tablets total)
 - trade card (inner)-30 tablets
 - trade card (outer)
 - trade wallet (contains 1 card)
 - trade carton (contains 1 wallet [30 tablets])
 - trade carton (contains 3 wallets [90 tablets])
- 10 mg/80 mg strength
 - foil sample (4 tablets)
 - sample carton (7 foil samples, 28 tablets total)
 - trade card (inner)-30 tablets
 - trade card (outer)
 - trade wallet (contains 1 card)
 - trade carton (contains 1 wallet [30 tablets])
 - trade carton (contains 3 wallets [90 tablets])

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

ERIC C COLMAN
05/16/2014